35results about "Endopeptidase" patented technology

A Bifidobacterium longum subsp longum produced by a method of growing the Bifidobacterium longum subsp longum in a culture medium, the culture medium containing a fructose disaccharide, FOS or combination thereof. A method for treatment or prevention of inflammatory bowel disease, celiac disease, non-celiac gluten sensitivity, gluten ataxia, dermatitis herpetiformis or wheat allergy in an individual, the method including administering a combination of (i) Bifidobacterium longum subsp longum and (ii) a fructose disaccharide, FOS or a combination thereof to the individual.

Use of a fructose disaccharide or fructooligosaccharide, for increasing protein production in Bifidobacterium longum subsp longum.

The invention relates to methods of assessing liver disease in a subject by detecting one or more single-nucleotide polymorphisms (SNPs) of the subject and correlating the detected SNPs to the liver disease. The methods may also include a step of implementing a treatment decision, such as monitoring the subject for signs of liver disease, administering a therapeutic agent to the subject, liver transplant, or combinations thereof. The invention also relates to computing devices for assessing liver disease in a subject.

This disclosure provides alpha-1 antitrypsin (AAT) polypeptides as defined herein. Also provided herein are pharmaceutical compositions comprising the polypeptide, nucleic acids encoding the polypeptide, vectors comprising the nucleic acid, cells, methods for producing the AAT polypeptide, and methods for using the AAT polypeptide in therapy.

The invention discloses a preparation method and application of a PSA-ACT compound recombinant protein. The preparation method comprises the following steps: obtaining gene segments of recombinant PSA and ACT proteins; respectively connecting the gene segments to starting vectors to form corresponding connectors; carrying out conversion and screening operation on the linker to obtain a corresponding recombinant plasmid; carrying out transformation, transfection, induction and fermentation broth separation and purification operation on the recombinant plasmid to obtain recombinant PSA and ACT proteins; then activating PSA recombinant protein by using metalloproteinase, and then mixing ACT with the activated PSA to obtain a mixture containing the PSA, ACT and a PSA-ACT compound; and finally, purifying by using an ion exchange chromatography technology and a hydrophobic chromatography technology in sequence to obtain the high-purity and high-activity PSA-ACT compound. According to the method, the spontaneous reaction of ACT and activated PSA is utilized, other chemical cross-linking agents are not needed, the cost can be reduced, and the recombinant protein can be produced on a large scale; the PSA-ACT recombinant protein prepared by the method disclosed by the invention has very strong immunoreactivity.

The present invention relates to extracts of bacteria of the genus Sphingomonas, compositions comprising at least one bacterium of the genus Sphingomonas or said extracts, their uses, and their implementation in cosmetic methods.

The problem to be solved by the present invention is to provide an extract of bacteria of the genus Sphingomonas, which may be used as an inhibitor of the kallikrein-kinin system and can reduce the occurrence of redness.SOLUTION: The present invention relates to an extract of bacteria of the genus Sphingomonas, to a composition comprising at least one bacterium of the genus Sphingomonas or said extract, to the uses thereof and to the implementation thereof in a cosmetic method.SELECTED DRAWING: None

Wound healing is a process by which these wounds on the skin of a subject heal and eventually close. When the injured surface is large, becomes infected, or in patients with poor healing capacity such as diabetics or the elderly or bedridden patients, then wound healing can be prolonged and lead to chronic ulceration and further complications with even limb loss or increased morbidity and mortality. This invention is directed to a topical formulation for promoting wound healing, and wound dressings and bandages comprising the same.

Disclosed herein are polypeptides that are useful for, among other things, inhibiting or suppressing the activity of a kallikrein-related protease and therefore treating diseases and conditions involving dysregulated kallikrein-related protease activity. Pharmaceutical compositions and therapeutic methods using the polypeptides and pharmaceutical compositions are also provided.

The application relates to the field of agricultural biotechnology, in particular to an LMSerpinb1 gene and application thereof. A locusta migratoria serpinb1 gene is cloned, and the locusta migratoria mortality and the gene expression amount change of the target gene in the locusta migratoria are detected through the method of mixed feeding of the locusta migratoria with metarhizium anisopliae, so that the role of the locusta migratoria in the metarhizium anisopliae infection is verified, and a foundation for further clarifying the action mechanism of Serpin is laid.

A peptide library comprising a plurality of different peptides. The peptides each comprise an amino acid sequence encoded by a nucleotide sequence consisting of the sequence of SEQ ID NO: 14. The nucleotide sequence has been modified by replacing a nucleotide sequence consisting of the 43rd base thymine to the 93rd base thymine with a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 1. The peptide library has a diversity of at least 1 × 105. In SEQ ID NO: 1, each of the 1st Xaa to the 5th Xaa, the 7th Xaa, the 9th Xaa, and the 10th Xaa in each peptide is independently any amino acid other than cysteine and proline. Each of the 6th Xaa and the 8th Xaa in each peptide is independently any amino acid other than cysteine. The 11th Xaa in each peptide is independently selected from tyrosine, serine, phenylalanine, leucine, and threonine. The 12th Xaa in each peptide is independently selected from asparagine, aspartic acid, leucine, lysine, glutamine, alanine, and glutamic acid.

The present invention provides methods and compositions for reducing internalization and / or trafficking of tau in neuronal cells comprising contacting the cells with an effective amount of an LRP1 and / or SorLA antagonist. The invention further provides a method of treating or preventing Alzheimer's disease in a subject in need thereof, comprising administering to the subject an effective amount of an LRP1 and / or SorLA antagonist.

Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.

Featured are cells and methods of use thereof for modulating an antigen-specific immune response in a subject. The cells comprise a set of transgenes comprising two or more of PD-L1, HLA-G or H2-M3, Cd47, Cd200, FASG or FasL, Ccl21 or Ccl21b, MfgeS and Serpin B9 or Spi6, that shield the cells from immune surveillance (ie. “cloaking genes”). The cells can be used to induce immune tolerance to an antigen (e.g., a donor alloantigen or a self-antigen), or to induce an immune response to (e.g., induce the production of antibodies directed against) a non-self antigen.

To provide a target binding peptide.SOLUTION: A target-binding peptide obtained by a method comprising the steps of: bringing a peptide contained in a peptide library into contact with a target molecule; recovering a peptide bound to the target molecule; and preparing the recovered peptide by gene recombination.SELECTED DRAWING: None

Described herein are systems and methods for modulating gene expression. Also described herein are systems and methods for treating a disease or a condition by modulating gene expression.

The present invention relates to protein prodrug constructs, e.g., protein fusion constructs, comprising complement 3 and pregnancy zone protein-like alpha-2-macroglobulin domain (CPAMD)-containing proteins (e.g., A2M) and one or more drugs, and acting as protease activatable prodrugs. The invention also relates to the release mechanism of the CPAMD protein and the development of multispecific drugs, such as bispecific drugs.

Described herein are systems and methods for modulating gene expression. Also described herein are systems and methods for treating a disease or a condition by modulating gene expression.

This invention belongs to the fields of molecular biology, genetic engineering, and protein engineering; specifically, it relates to a Pacifastin serine protease inhibitor PqPI expressed in the venom of the grassland caterpillar wasp, its encoded nucleic acid sequence, and functional studies. This invention provides a Pacifastin serine protease inhibitor PqPI from the grassland caterpillar wasp, which has the amino acid sequence shown in SEQ ID NO:2. This invention also provides the use of the above-mentioned Pacifastin serine protease inhibitor PqPI from the grassland caterpillar wasp: for the preparation of Pacifastin serine protease inhibitors from the grassland caterpillar wasp, which can be used to inhibit the activation of PPO in the hemolymph of grassland caterpillars or cabbage caterpillars.

A method, system, and composition related to the preparation of samples for glycoproteomic analysis is described. The sample preparation process can include a proteolytic digestion step followed by a measurement step of the glycopeptide and peptide amounts in the proteolytic digest using a liquid chromatography-mass spectrometry system. Optionally, the sample preparation process can also include the collection of the sample on an absorbent or bibulous member where the proteins and glycoproteins are later extracted and then digested for glycoproteomic analysis. Glycopeptide and peptide measurements of biological samples were analyzed to provide a diagnosis of a disease such as, for example, ovarian cancer or to assess whether a patient with melanoma is likely or not likely to benefit from checkpoint inhibitor therapy.

The present invention relates to the diagnosis and treatment of diseases expressing Fibronectin Extra Domain B (EDB) such as diseases characterized by tissue remodeling and / or angiogenesis, in particular cancerous diseases, such as head and neck, brain, colorectal, lung, prostate and breast cancer. More particularly, the invention concerns peptides targeting Fibronectin Extra Domain B.

The application discloses application of ZPI as a target point in specific marking and identification of mature follicle. When micro-proteome detection is carried out on oocytes at various development stages of human, it is found that the expression of some proteins of the oocytes has development stage specificity. After screening of the proteins specifically expressed at the pre-ovulation stage and comparison with the Human Protein Atlas database, the GEO database, the PubMED database and published mRNA data, it is found that ZPI is highly expressed in the oocyte before ovulation, and immunohistochemistry of the ovarian section proves that ZPI is specifically expressed in the pre-ovulation follicle. Therefore, it is proposed that the ZPI molecule can be applied as a target point to specific identification and targeting of mature follicle and other related experimental technologies, to assist scholars in identifying and judging the development period and ovulation period of the oocyte, and to promote the molecular biology research on the physiology and pathology mechanism of the oocyte or follicle maturation.

The present invention relates to proteinaceous prodrug constructs, e.g., proteinaceous fusion constructs that comprise a complement 3- and pregnancy zone protein-like, alpha-2 -macroglobulin domain-containing (CPAMD) protein (e.g., A2M) and one or more drugs and function as protease- activatable prodrugs. The invention further relates to a release mechanism from the CPAMD protein and the development of multispecific, such as bi-specific, drugs.

The present invention relates to the use of elafin or a homologue, fragment or derivative thereof in the treatment of COVID-19, in particular any disorder or disease associated with an infection with the SARS-CoV-2 virus. The present invention also relates to a respective method of treatment for COVID-19 and composition comprising elafin or a homologue, fragment or derivative thereof for use in said treatment. The present invention additionally or concomitantly relates to the use of elafin or a homologue, fragment or derivative thereof for the treatment and / or prevention of complications associated with COVID-19 and / or progression to severe disease upon infection with SARS-CoV-2 virus.